We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+9.38%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$162M
AUM Growth
+$43M
Cap. Flow
+$46.5M
Cap. Flow %
28.77%
Top 10 Hldgs %
56.19%
Holding
71
New
20
Increased
17
Reduced
10
Closed
20

Top Buys

Rank Stock Value
1
AGTC
Applied Genetic Technologies Corporation
AGTC
+$14.3M
2
VCYT icon
Veracyte
VCYT
+$7.86M
3
SPNC
Spectranetics Corp
SPNC
+$6.98M
4
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$3.6M
5
ASND icon
Ascendis Pharma A/S
ASND
+$3.38M

Top Sells

Rank Stock Value
1
CEMP
Cempra, Inc.
CEMP
+$5.49M
2
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$3.74M
3
INSM icon
Insmed
INSM
+$3.12M
4
FOLD
Amicus Therapeutics
FOLD
+$2.28M
5
CORV
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
+$2.2M

Sector Composition

Rank Sector Weight
1 Healthcare 81.09%
2 Consumer Discretionary 1.98%
3 Industrials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$25.1M 15.53%
1,775,000
-189,565
-10% -$2.28M
AGTC
2
DELISTED
Applied Genetic Technologies Corporation
AGTC
$11.5M 7.09%
+748,000
New +$14.3M
VCYT icon
3
Veracyte
VCYT
$3.58B
$8.89M 5.5%
+798,100
New +$7.86M
IWM icon
4
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$8.74M 5.4%
70,000
+50,000
+250% +$6.25M
IOVA icon
5
Iovance Biotherapeutics
IOVA
$1.93B
$8.13M 5.02%
886,000
+216,804
+32% +$2.42M
ASND icon
6
Ascendis Pharma A/S
ASND
$16B
$7.46M 4.61%
421,851
+193,239
+85% +$3.38M
BEAT
7
DELISTED
BioTelemetry, Inc.
BEAT
$6.22M 3.85%
660,000
+178,931
+37% +$1.66M
SPNC
8
DELISTED
Spectranetics Corp
SPNC
$5.75M 3.56%
+250,000
New +$6.98M
NDRM
9
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.61M 2.85%
300,000
+196,833
+191% +$2.77M
ALIM
10
DELISTED
Alimera Sciences
ALIM
$4.49M 2.78%
64,955
-5,366
-8% -$370K
AGEN
11
Agenus
AGEN
$326M
$3.83M 2.37%
+22,615
New +$3.21M
SRNE
12
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$3.74M 2.31%
+212,402
New +$2.73M
INNL
13
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$3.47M 2.15%
237,287
+72,828
+44% +$808K
SIOX
14
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.46M 2.14%
+21,250
New +$3.6M
BBW icon
15
Build-A-Bear
BBW
$424M
$3.2M 1.98%
200,000
+50,000
+33% +$885K
RRM
16
DELISTED
RR MEDIA LTD ORD SHS (ISR)
RRM
$3.08M 1.91%
410,000
+4,576
+1% +$33.2K
AVID
17
DELISTED
Avid Technology Inc
AVID
$3.07M 1.9%
230,000
+129,182
+128% +$2.06M
LMAT icon
18
LeMaitre Vascular
LMAT
$2.37B
$3.02M 1.86%
250,000
-216,279
-46% -$2.13M
CASM
19
DELISTED
CAS Medical Systems, Inc.
CASM
$3.02M 1.86%
2,355,355
+195,355
+9% +$254K
ALBO
20
DELISTED
Albireo Pharma Inc
ALBO
$2.97M 1.84%
+96,224
New +$3.23M
TLGT
21
DELISTED
Teligent, Inc
TLGT
$2.92M 1.8%
+46,294
New +$3.13M
CYNA
22
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$2.76M 1.71%
+169,616
New +$2.78M
OXFD
23
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.74M 1.69%
197,680
-24,546
-11% -$332K
IRIX icon
24
IRIDEX
IRIX
$14.4M
$2.58M 1.59%
312,450
+76,933
+33% +$718K
CASC
25
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.51M 1.55%
+111,667
New +$1.77M
1
2 3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2015 Portfolio in Review

As of Q2 2015, Acuta Capital Partners held 71 positions worth $162M, up 36% from $119M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Acuta Capital Partners deployed $46.5M of net new capital in Q2 2015, opening 20 new positions and adding to 17 existing holdings. Its largest new stake was Applied Genetic Technologies Corporation: 748,000 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 80% a quarter earlier, followed by Consumer Discretionary and Industrials.

On the sell side, the largest reduction was Cempra, Inc., an estimated $5.49M trimmed.

  • Acuta Capital Partners's largest Q2 2015 buy was Applied Genetic Technologies Corporation: 748,000 shares worth $11.5M.
  • Acuta Capital Partners added most to Ascendis Pharma A/S in Q2 2015, an estimated $3.38M increase.
  • Acuta Capital Partners's biggest Q2 2015 reduction was Cempra, Inc., cutting an estimated $5.49M.
  • Acuta Capital Partners fully exited Pernix Therapeutics Holdings, Inc. in Q2 2015, selling an estimated $3.74M.
  • Acuta Capital Partners's ten largest holdings make up 56% of its $162M portfolio in Q2 2015.
  • Acuta Capital Partners opened 20 new positions and closed 20 in Q2 2015.
  • Acuta Capital Partners's portfolio value rose 36% quarter-over-quarter to $162M.

Based on Acuta Capital Partners's 13F filing for Q2 2015, filed 14 Aug 2015.